IBRN vs. IDNA
Compare and contrast key facts about iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA).
IBRN and IDNA are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IBRN is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Neuro Biopharma and MedTech Index. It was launched on Aug 24, 2022. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. Both IBRN and IDNA are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Performance
IBRN vs. IDNA - Performance Comparison
Loading graphics...
IBRN vs. IDNA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
IBRN iShares Neuroscience and Healthcare ETF | 1.98% | 28.49% | -2.78% | 0.92% | 5.85% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 11.45% | 17.26% | -0.72% | -7.63% | -16.77% |
Returns By Period
In the year-to-date period, IBRN achieves a 1.98% return, which is significantly lower than IDNA's 11.45% return.
IBRN
- 1D
- 7.11%
- 1M
- 2.75%
- YTD
- 1.98%
- 6M
- 24.24%
- 1Y
- 48.96%
- 3Y*
- 11.91%
- 5Y*
- —
- 10Y*
- —
IDNA
- 1D
- 0.48%
- 1M
- -5.56%
- YTD
- 11.45%
- 6M
- 20.68%
- 1Y
- 48.06%
- 3Y*
- 9.03%
- 5Y*
- -7.93%
- 10Y*
- —
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IBRN vs. IDNA - Expense Ratio Comparison
Both IBRN and IDNA have an expense ratio of 0.47%.
Return for Risk
IBRN vs. IDNA — Risk / Return Rank
IBRN
IDNA
IBRN vs. IDNA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IBRN | IDNA | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.68 | 1.75 | -0.07 |
Sortino ratioReturn per unit of downside risk | 2.32 | 2.40 | -0.08 |
Omega ratioGain probability vs. loss probability | 1.29 | 1.29 | 0.00 |
Calmar ratioReturn relative to maximum drawdown | 2.53 | 3.66 | -1.13 |
Martin ratioReturn relative to average drawdown | 9.59 | 11.65 | -2.06 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| IBRN | IDNA | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.68 | 1.75 | -0.07 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | — | -0.28 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.11 | +0.25 |
Correlation
The correlation between IBRN and IDNA is 0.78, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Dividends
IBRN vs. IDNA - Dividend Comparison
IBRN's dividend yield for the trailing twelve months is around 0.97%, less than IDNA's 1.06% yield.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
IBRN iShares Neuroscience and Healthcare ETF | 0.97% | 0.99% | 0.40% | 0.06% | 0.00% | 0.00% | 0.00% | 0.00% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.06% | 1.18% | 0.98% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% |
Drawdowns
IBRN vs. IDNA - Drawdown Comparison
The maximum IBRN drawdown since its inception was -35.38%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for IBRN and IDNA.
Loading graphics...
Drawdown Indicators
| IBRN | IDNA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -35.38% | -68.26% | +32.88% |
Max Drawdown (1Y)Largest decline over 1 year | -15.44% | -12.11% | -3.33% |
Max Drawdown (5Y)Largest decline over 5 years | — | -68.26% | — |
Current DrawdownCurrent decline from peak | -1.72% | -45.05% | +43.33% |
Average DrawdownAverage peak-to-trough decline | -10.20% | -36.05% | +25.85% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.62% | 3.81% | +0.81% |
Volatility
IBRN vs. IDNA - Volatility Comparison
iShares Neuroscience and Healthcare ETF (IBRN) has a higher volatility of 12.31% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 9.54%. This indicates that IBRN's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| IBRN | IDNA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.31% | 9.54% | +2.77% |
Volatility (6M)Calculated over the trailing 6-month period | 19.64% | 18.22% | +1.42% |
Volatility (1Y)Calculated over the trailing 1-year period | 29.56% | 27.75% | +1.81% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.40% | 28.53% | -3.13% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 25.40% | 29.68% | -4.28% |